What topics does this cannabis study cover?

This study covers research on: Epilepsy.

Where was this research published?

Published in Epilepsia on January 19, 2026.

Unlocking brain potential: How seizure medications impact cognitive function

Q: What did this Review find?

**Interictal epileptiform discharges (IEDs) actively contribute to cognitive dysfunction**, not just passive markers of epilepsy

Seizure medications and interictal spiking: Implications for cognition and behavior.

Epilepsia • January 19, 2026 • Review • Relevant

🤖

AI Summary

This comprehensive review explores the complex world of antiseizure medications (ASMs) and their impact on brain function beyond seizure control. Researchers have discovered that interictal epileptiform discharges (IEDs) are not just passive markers of epilepsy, but active contributors to cognitive and behavioral challenges. The study reveals that certain medications can effectively suppress these discharges, potentially improving mental performance and behavioral outcomes.

The research highlights several promising treatment approaches, with particular emphasis on broad-spectrum medications that can reduce IEDs. Cannabidiol emerges as an especially interesting therapeutic option, showing promising results in reducing both interictal discharges and behavioral symptoms. The study suggests that targeted reduction of these neural discharges could lead to significant improvements in cognitive function, particularly in children with epilepsy. Animal studies further support these findings, demonstrating that suppressing IEDs can enhance memory, attention, and social behaviors.

💡 Key Findings

Interictal epileptiform discharges (IEDs) actively contribute to cognitive dysfunction, not just passive markers of epilepsy

High

85%

Broad-spectrum medications like valproate and lamotrigine can suppress IEDs, potentially improving cognitive performance

Good

75%

Cannabidiol shows promising outcomes in reducing interictal discharges and behavioral symptoms

Good

65%

📄 Original Abstract

Interictal epileptiform discharges (IEDs) are not just biomarkers but active contributors to cognitive and behavioral dysfunction. Antiseizure medications (ASMs) not only treat seizures but can also modulate IEDs. However, their broader neurocognitive impact remains underexplored. The goal of this review is to synthesize current evidence on ASM effects on IEDs and to examine their therapeutic implications for cognitive and behavioral improvement. A comprehensive literature search was conducted, focusing on studies that reported ASM-related IED modulation and associated cognitive or behavioral measures. ASMs demonstrate variable efficacy in reducing IEDs, with broad-spectrum agents like valproate and lamotrigine showing consistent suppression of IEDs resulting in cognitive benefit, particularly in children. The use of sodium channel blockers, such as lamotrigine and oxcarbazepine, produces cognitive improvements. Additionally, γ-aminobutyric acidergic agents, including clobazam and diazepam, are effective in treating developmental epileptic encephalopathies. Emerging therapies, including cannabidiol and perampanel, show promising IED and behavioral outcomes. Animal studies confirm that ASMs can suppress IEDs, leading to enhanced memory, attention, and social behaviors. Targeted reduction of IEDs may lead to improved cognitive and behavioral outcomes. This can be achieved by testing and recognizing ASMs in carefully designed prospective trials in animals and humans.